<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766998</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00021450</org_study_id>
    <nct_id>NCT02766998</nct_id>
  </id_info>
  <brief_title>Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery</brief_title>
  <official_title>Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single center, safety and feasibility trial to evaluate the use of&#xD;
      autologous umbilical vein as shunts or conduits in neonatal cardiac surgery. Subjects will be&#xD;
      identified here at the Advanced Fetal Care Center (AFCC) following diagnosis of congenital&#xD;
      heart disease (CHD) with single ventricle physiology of the fetus via fetal echocardiogram.&#xD;
      At time of cesarean section or vaginal delivery, umbilical cord will be harvested in a&#xD;
      sterile fashion and the umbilical vein will be dissected free and preserved until first&#xD;
      clinically indicated Stage I palliative procedure between day 3 and 7 of life. Subjects will&#xD;
      be followed until their Stage II palliative procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absense of primary serious adverse events</measure>
    <time_frame>from time of insertion to time of Stage II procedure, approximately 6 months</time_frame>
    <description>Primary SAEs are defined as:&#xD;
Bleeding from shunt/conduit requiring intervention (either medical or surgical)&#xD;
Shunt/conduit thrombosis&#xD;
Shunt/conduit infection with positive culture of preservative solution or positive clinical culture following implantation of umbilical vein&#xD;
Aneurysm of shunt/conduit</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Congenital Heart Defects</condition>
  <arm_group>
    <arm_group_label>Preserved umbilical vein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preserved umbilical vein as shunt/conduit</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preserved umbilical vein as shunt/conduit</intervention_name>
    <description>All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.</description>
    <arm_group_label>Preserved umbilical vein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All fetal diagnoses of complex congenital heart disease diagnosed by fetal&#xD;
             echocardiogram requiring cardiac repair with Blalock-Taussig Shunt or Right Ventricle&#xD;
             to Pulmonary Artery conduit will be eligible.&#xD;
&#xD;
          -  This includes all pre-natal diagnoses of any single ventricle circulation physiology&#xD;
             (SVP).&#xD;
&#xD;
          -  Subjects being delivered via cesarean section or vaginally at Brigham and Women's&#xD;
             Hospital will be considered.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  meconium at delivery&#xD;
&#xD;
          -  symptomatic Group B Streptococcus (GBS) positive mothers&#xD;
&#xD;
          -  mothers with chorioamnionitis&#xD;
&#xD;
          -  Hepatitis B or C positive mothers&#xD;
&#xD;
          -  HIV positive mothers.&#xD;
&#xD;
          -  If unable to collect viable cord on the day of delivery of already enrolled subjects,&#xD;
             the subject will be removed from the study on day of birth.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sitaram Emani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Breanna Piekarski, RN, BSN</last_name>
    <phone>617-919-4457</phone>
    <email>breanna.piekarski@cardio.chboston.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Hoganson, MD</last_name>
    <email>david.hoganson@cardio.chboston.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanna Piekarski, RN, BSN</last_name>
      <phone>617-919-4457</phone>
      <email>breanna.piekarski@cardio.chboston.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>David Hoganson</investigator_full_name>
    <investigator_title>Assistant in Cardiac Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

